Skip to main content

Table 2 Treatment status of patients

From: The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902)

 

Induction therapy

CapeOX + BEV

(N = 52)

Maintenance therapy

Capecitabin + BEV

(N = 45)

Reintoroduction therapy

CapeOX + BEV

(N = 29)

Treatment cycle, times

 Median (range)

4 (2–4)

7 (1–8)

5 (1–21)

Median relative dose-intensity, %

 Oxaliplatin

92.3

-

78.5

 Capecitabin

92.0

82.4

71.8

 Bevacizumab

96.6

92.0

91.0

Total dose of oxaliplatin, mg

 Median (range)

1052 (470–4346)

Time-to-treatment failuer, months

 Median (95% CI)

9.9 (5.9–13.8)

Post progression treatment, n (%)

 Second-line therapy

46

(88.5)

 Anti-EGFR agents

17

(32.7)

 Bevacizumab (BBP)

35

(67.3)

 Resection of metastasis

8

(15.4)

  1. BEV bevacizumab, N total number of patients, CI confidence interval, BBP Bevacizumab beyond progression